↓ Skip to main content

Prostate Cancer Prevention

Overview of attention for book
Cover of 'Prostate Cancer Prevention'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 The Biology and Natural History of Prostate Cancer: A Short Introduction
  3. Altmetric Badge
    Chapter 2 Germline genetic variants associated with prostate cancer and potential relevance to clinical practice.
  4. Altmetric Badge
    Chapter 3 Lifestyle and Dietary Factors in Prostate Cancer Prevention
  5. Altmetric Badge
    Chapter 4 Nutrition, Hormones and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition
  6. Altmetric Badge
    Chapter 5 Screening for Prostate Cancer: Current Status of ERSPC and Screening-Related Issues
  7. Altmetric Badge
    Chapter 6 Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
  8. Altmetric Badge
    Chapter 7 ERSPC, PLCO Studies and Critique of Cochrane Review 2013
  9. Altmetric Badge
    Chapter 8 Screening for Prostate Cancer: Reflecting on the Quality of Evidence from the ERSPC and PLCO Studies.
  10. Altmetric Badge
    Chapter 9 Phase III Prostate Cancer Chemoprevention Trials
  11. Altmetric Badge
    Chapter 10 Risk Adapted Chemoprevention for Prostate Cancer: An Option?
  12. Altmetric Badge
    Chapter 11 Aspirin and Prostate Cancer Prevention
  13. Altmetric Badge
    Chapter 12 Chemoprevention of Prostate Cancer by Isoflavonoids
  14. Altmetric Badge
    Chapter 13 Lycopene for the prevention and treatment of prostate disease.
  15. Altmetric Badge
    Chapter 14 Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.
  16. Altmetric Badge
    Chapter 15 Prostate Cancer Prevention: Agent Development Strategies
  17. Altmetric Badge
    Chapter 16 Prognostic Value of a Cell Cycle Progression Score for Men with Prostate Cancer
  18. Altmetric Badge
    Chapter 17 Distinguishing Indolent from Aggressive Prostate Cancer
  19. Altmetric Badge
    Chapter 18 Management of Low Risk and Low PSA Prostate Cancer: Long Term Results from the Prostate Cancer Intervention Versus Observation Trial
Attention for Chapter 14: Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
21 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.
Chapter number 14
Book title
Prostate Cancer Prevention
Published in
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, February 2014
DOI 10.1007/978-3-642-45195-9_14
Pubmed ID
Book ISBNs
978-3-64-245194-2, 978-3-64-245195-9
Authors

Meyskens FL Jr, Simoneau AR, Gerner EW, Frank L. Meyskens, Anne R. Simoneau, Eugene W. Gerner, Meyskens, Frank L., Simoneau, Anne R., Gerner, Eugene W.

Abstract

In vitro and in vivo preclinical results suggest that inhibition of polyamine synthesis inhibits the progression of prostate cancer. These findings has led to two clinical trials in patients at risk for invasive prostate cancer with difluoromethylornithine which specifically and irreversibly inhibits ornithine decarboxylase which catalyses the conversion of ornithine to putrescine the rate limiting step in polyamines synthesis. We have conducted a phase IIa one month and placebo randomized phase IIb 12 months trials in patients at increased risk for invasive prostate cancer. Favorable reduction in prostate polyamine levels and prostate volume was documented with no difference in clinical hearing changes. Patients with Gleason's VI lesions in a surveillance cohort would be appropriate candidates for a definitive risk reduction trial although the unavailability of validated biomarkers for invasive progression would require a large and lengthy study.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 19%
Student > Bachelor 3 14%
Lecturer 2 10%
Other 2 10%
Researcher 2 10%
Other 4 19%
Unknown 4 19%
Readers by discipline Count As %
Medicine and Dentistry 7 33%
Biochemistry, Genetics and Molecular Biology 3 14%
Computer Science 2 10%
Agricultural and Biological Sciences 1 5%
Immunology and Microbiology 1 5%
Other 1 5%
Unknown 6 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2014.
All research outputs
#18,369,403
of 22,751,628 outputs
Outputs from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#119
of 171 outputs
Outputs of similar age
#163,755
of 224,139 outputs
Outputs of similar age from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#3
of 3 outputs
Altmetric has tracked 22,751,628 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 171 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 224,139 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.